Northern Trust Corp acquired a new position in Entera Bio Ltd. (NASDAQ:ENTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 212,483 shares of the company's stock, valued at approximately $450,000. Northern Trust Corp owned 0.59% of Entera Bio at the end of the most recent reporting period.
Separately, Perigon Wealth Management LLC acquired a new stake in shares of Entera Bio during the 4th quarter valued at about $325,000. Institutional investors and hedge funds own 14.11% of the company's stock.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Entera Bio in a research report on Tuesday, March 18th.
Check Out Our Latest Research Report on ENTX
Entera Bio Stock Down 1.3%
Shares of NASDAQ ENTX traded down $0.03 during midday trading on Wednesday, hitting $2.05. The stock had a trading volume of 2,055 shares, compared to its average volume of 70,355. Entera Bio Ltd. has a 1 year low of $1.41 and a 1 year high of $2.79. The company has a market capitalization of $93.13 million, a PE ratio of -7.88 and a beta of 1.51. The stock has a 50 day simple moving average of $1.93 and a 200-day simple moving average of $2.05.
Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The business had revenue of $0.04 million during the quarter. As a group, analysts expect that Entera Bio Ltd. will post -0.28 earnings per share for the current fiscal year.
About Entera Bio
(
Free Report)
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Recommended Stories
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
